Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 dose-response study of sodium zirconium cyclosilicate in Japanese patients with hyperkalemia
jRCT2080223526Phase 3
- Sponsor
- AstraZeneca
- Start
- May 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sodium zirconium cyclosilicate in hyperkalemia (3 arms), sponsored by AstraZeneca.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on jRCT2080223526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223526.